Bliss GVS Pharma Limited

NSE:BLISSGVS.NS

134.15 (INR) • At close September 16, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 7,702.4497,515.8757,379.2855,686.8756,819.18,861.0943,638.2457,997.4095,468.9414,071.3443,468.6843,966.2542,666.7492,188.3811,688.7531,329.5571,023.959623.392
Cost of Revenue 5,040.7994,013.2493,909.823,289.094,399.7346,122.5651,942.2973,593.412,567.6531,775.4651,706.3072,038.0971,574.7171,273.943905.725698.406445.944356.586
Gross Profit 2,661.653,502.6263,469.4652,397.7852,419.3662,738.5291,695.9484,403.9992,901.2882,295.8791,762.3771,928.1571,092.032914.438783.028631.151578.015266.806
Gross Profit Ratio 0.3460.4660.470.4220.3550.3090.4660.5510.5310.5640.5080.4860.4090.4180.4640.4750.5640.428
Reseach & Development Expenses 152.297217.888213.796104.00776.887142.57825.10436.8132.087000000000
General & Administrative Expenses 84.07672.76588.75169.69560.43572.1943.281410.781574.392410.38247.35745.635000000
Selling & Marketing Expenses 346.806421.652451.776209.511211.374204.689153.24212.683318.507353.487351.168402.602000000
SG&A 1,419.222494.417540.527279.206271.809276.879196.521623.464892.899763.869828.432658.943000000
Other Expenses 287.374177.86425.48327.4114.6285.71288.83319.74726.77126.7735.5832.902000000
Operating Expenses 1,419.2222,516.1342,288.7211,487.8191,282.8611,140.259812.5662,668.5271,386.6311,374.4491,134.73874.675257.534363.15305.036205.997211.863201.506
Operating Income 1,242.428986.4921,013.157894.4711,111.4661,510.6891,064.8631,915.831,732.7881,114.094627.6471,045.772834.498551.287477.993425.154366.15365.3
Operating Income Ratio 0.1610.1310.1370.1570.1630.170.2930.240.3170.2740.1810.2640.3130.2520.2830.320.3580.105
Total Other Income Expenses Net -73.70874.224-471.504146.799178.184308.463-424.92-124.039-250.841-153.90277.93549.052-40.305-21.473-20.441-22.619-13.834-6.663
Income Before Tax 1,168.721,060.716541.6531,041.271,289.6511,819.131639.9431,791.7911,481.947960.192705.5821,094.824794.193529.814457.552402.535352.31958.637
Income Before Tax Ratio 0.1520.1410.0730.1830.1890.2050.1760.2240.2710.2360.2030.2760.2980.2420.2710.3030.3440.094
Income Tax Expense 352.941291.542310.388301.554337.123552.504322.693628.409480.491346.258295.267498.978268.835123.51140.33728.02314.96620.228
Net Income 754.541708.588150.402684.909972.651,237.216587.853856.106824.826599.097409.917577.201525.358406.303417.215374.512337.35338.409
Net Income Ratio 0.0980.0940.020.120.1430.140.1620.1070.1510.1470.1180.1460.1970.1860.2470.2820.3290.062
EPS 7.236.831.466.649.4311.995.77.9585.813.975.65.093.944.043.632.046.53
EPS Diluted 7.116.721.436.499.4311.995.77.9585.813.975.65.093.944.043.632.046.53
EBITDA 1,506.2261,351.0891,650.1621,272.1871,619.6742,059.2961,278.6922,121.3411,875.2991,236.966739.721,107.016870.959605.982532.004461.068395.41994.47
EBITDA Ratio 0.1960.180.2240.2240.2380.2320.3510.2650.3430.3040.2130.2790.3270.2770.3150.3470.3860.152